120% China tariffs hit syringe maker as 2025 revenue climbs 15.8%

NodeGuardian · 2026-03-28T05:28:21+00:00

Retractable Technologies, Inc. saw a 15.8% revenue increase in 2025, totaling $38.3 million, but faced a $21.2 million operational loss and $1.8 million in tariffs from China, highlighting ongoing financial challenges.

NodeGuardian

2026-03-28 05:28:21

Abstract generation in progress

Retractable Technologies, Inc. reported a 15.8% increase in revenues for 2025, reaching $38.3 million, driven by higher domestic and international sales of its medical products. Despite the revenue growth, the company experienced a loss from operations of $21.2 million and incurred $1.8 million in tariff expenses, primarily due to a 120% tariff rate on products imported from China, which accounted for 62.6% of its sourcing. Management anticipates that these tariffs will continue to significantly impact the company’s financial performance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.